Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.

Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review

Recession signals are popping up on a daily basis.

Horizon Therapeutics: A Recession Resistant Pick With Upside Potential

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Why Is Horizon Therapeutics (HZNP) Down 3.3% Since Last Earnings Report?

Horizon Therapeutics PLC (NASDAQ: HZNP), an actively traded small-cap biotech, is poised for further upside in the near-term on its product strength, according to BMO Capital Markets.

Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade

EVP, Corporate Affairs, CCO of Horizon Therapeutics Plc (30-Year Financial, Insider Trades) Geoffrey M.

Horizon Therapeutics Plc (HZNP) EVP, Corporate Affairs, CCO Geoffrey M. Curtis Sold $547,787 of Shares

Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.

Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates

Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q2 2019 Results - Earnings Call Transcript

Horizon Therapeutics earnings and revenue rose slightly, defying Q2 views for year-over-year declines. Shares weren't active early.

Horizon Earnings Unexpectedly Rise

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Horizon Therapeutics (HZNP) Q2 Earnings Expected to Decline

Activision Blizzard

Conagra Brands

Cerner

Incyte

NetScout Systems

Ollie's Bargain Outlet Hlds

Public Service Enterprise Group

Sealed Air

Urstadt Biddle Properties

With August now upon us, not only is the overbought market vulnerable to profit-taking, the calendar is working against stocks as well. One average, the market loses ground rather than gains ground in the month of August, as well as for September.

The 10 Best Stocks to Invest in for August

The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.

Horizon's NDA for Procysbi New Dosage Form Accepted by FDA

Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.

Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

Strong growth for its orphan, rheumatology, and primary care drugs translated to a great first quarter for Horizon.

Here's How Horizon Therapeutics Blew Past Wall Street Estimates in Q1

Horizon Therapeutics PLC (HZNP) CEO Tim Walbert on Q1 2019 Results - Earnings Call Transcript

Horizon Pharma (HZNP) delivered earnings and revenue surprises of 200.00% and 18.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Horizon Pharma (HZNP) Q1 Earnings and Revenues Top Estimates

Horizon Pharma on Wednesday reported adjusted income of 30 cents per share on $280.4 million in sales for its first quarter. In the year-earlier period, Horizon earnings were 3 cents.

Horizon Earnings Trounce Views; Stock Near Buy Point

Horizon Pharma (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Horizon Pharma (HZNP) Reports Next Week: Wall Street Expects Earnings Growth

Horizon Pharma reported overwhelmingly positive phase 3 results of teprotumumab in thyroid eye disease ('TED').

Horizon Pharma: Teprotumumab To Become A Key Commercial Asset In The 2020s

Horizon Pharma (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Horizon Pharma (HZNP)

Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock?

Why Is Horizon Pharma (HZNP) Down 9.9% Since Last Earnings Report?

The company reported top line Phase III clinical results of Teprotumumab showing a dramatic reduction of proptosis versus placebo.

Horizon Pharma: Teprotumumab Opportunity Not Fully Priced In

Recently, Horizon Pharma (HZNP) announced that it had achieved positive results from a phase 3 study using teprotumumab in treating patients with thyroid eye disease (TED).

Horizon's Past Biotech Purchase Has Paid Off In A Great Way

Horizon Pharma stock jumped Friday on an upgrade despite a recent Department of Justice investigation. The analyst has bullish views on its rare disease and rheumatology treatments.

News for Horizon Pharma Stock (HZNP)